Avalo Therapeutics Inc. may have designed in lead asset abdakibart, a drug for hidradenitis suppurativa (HS) that offers a ...

The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to ...

The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to commercial success. For Link Biologics and its TSG6-based pipeline, the story is ...

Researchers from Flare Therapeutics Inc. presented the preclinical profile of FX-111, a selective active androgen receptor ...

Ltd. has prepared and tested new tricyclic compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12V mutant) interaction inhibitors potentially useful for the treatment of cancer.

UCB SA agreed to pay $2 billion up front to acquire bispecific T-cell engager (TCE)-maker Candid Therapeutics Inc. and lead ...

Three years after Johnson & Johnson handed back rights to an siRNA candidate targeting a genetic driver of metabolic dysfunction-associated steatohepatitis (MASH), Arrowhead Pharmaceuticals Inc. found ...

Pacific, including deals and partnerships, and other news in brief: AC Immune, Aptose, Cipla, Dexcel, Hanmi Hikma, Noxopharm, Pfizer, Takeda.

China’s investigator-initiated trial (IIT) system is increasingly being used to generate early human data in cell and gene therapies, and new changes that widen the pathway are expected to drive more ...

Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity ...

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a ...

Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the ...